I2Pure Corporation, a Virginia-based antimicrobial technology developer, has reported peer-reviewed laboratory findings showing that three proprietary molecular iodine formulations rapidly killed several clinically important drug-resistant bacteria and fungi, frequently achieving reductions exceeding 99.9% within 15 seconds of contact. Announced on October 12, 2026, the research evaluated 17 bacterial and fungal strains, including methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecalis and Candidozyma auris, while also investigating antimicrobial activity after drying and staining of hospital textiles.
The study, conducted by researchers at the University of California San Diego and published in Antimicrobial Agents and Chemotherapy, found that molecular iodine preparations produced substantial reductions in recoverable microorganisms under controlled laboratory conditions. Investigators also reported that the formulations were considerably easier to remove from tested hospital fabrics than conventional povidone-iodine, with residual antimicrobial activity demonstrated after 24 hours of drying on experimental filter-paper surfaces. However, the findings do not establish that the products prevent healthcare-associated infections, outperform established antiseptics in patients or qualify for unrestricted hospital disinfection use.
The research is commercially relevant because hospitals face continuing challenges involving multidrug-resistant organisms, infection-control procedures and the practical limitations of existing antiseptic products. I2Pure is developing molecular iodine technology for applications including topical antisepsis, nasal decolonization and healthcare surface treatment, with the aim of retaining iodine’s broad antimicrobial activity while reducing staining and improving formulation flexibility. The next question is whether these laboratory advantages can be reproduced under actual healthcare conditions, supported by appropriate safety evidence and regulatory authorisation for each intended use.
What did the I2Pure study demonstrate against 17 bacterial and fungal strains?
The research evaluated three iodine-based preparations described as a soak formulation, a nasal antiseptic and a skin ointment or hand antiseptic. Investigators examined activity against 13 bacterial strains and four fungal strains using quantitative laboratory assays that measured surviving colony-forming units after exposure. The experiments used contact times of 15, 30 and 60 seconds, allowing comparisons of how antimicrobial performance changed with concentration and exposure duration.
The bacterial panel included methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus faecalis (VRE), Klebsiella pneumoniae, Pseudomonas aeruginosa, Acinetobacter baumannii and several additional clinically relevant organisms. The fungal panel included Candida albicans, Candidozyma auris, Aspergillus fumigatus and Aspergillus brasiliensis. These organisms are relevant to infection prevention because they include pathogens associated with difficult-to-treat infections, antimicrobial resistance and healthcare-associated transmission.
Across many tested organisms, the molecular iodine formulations produced reductions of three to four logarithmic units in recoverable microorganisms within 15 seconds. A three-log reduction corresponds to a 99.9% decline in viable organisms, while a four-log reduction represents 99.99%. These figures describe the reduction achieved under specific experimental conditions, not a measured decrease in patients developing infections.
The results were not uniform across every organism and formulation. Certain bacteria, including group A streptococci and enterococci, required longer contact times or higher iodine concentrations for maximal killing. The fungal experiments also revealed important differences, particularly with Aspergillus brasiliensis, against which the nasal antiseptic and skin ointment did not demonstrate effective killing at the tested exposure times.
The study therefore supports broad antimicrobial activity, but not an assertion that every formulation eliminated every tested pathogen within 15 seconds. The actual performance depends on the organism, iodine concentration, formulation and contact conditions.
Why is activity against MRSA, VRE and Candida auris important for hospital infection prevention?
Antimicrobial resistance creates substantial challenges for hospitals because certain bacterial and fungal infections are difficult to treat with available medicines. MRSA and VRE are familiar healthcare-associated threats, while Candidozyma auris, widely known as Candida auris, has attracted particular attention because of its capacity to spread in healthcare facilities and its resistance to some antifungal treatments. Reducing environmental or skin-associated microbial contamination can form part of infection prevention, although laboratory antimicrobial activity alone does not establish prevention of transmission.
The I2Pure findings are particularly relevant because molecular iodine acts through mechanisms different from those of conventional antibiotics. Active iodine can damage proteins, membrane components and nucleic acids through oxidative interactions, affecting several microbial structures rather than relying on one specific drug target. This broad mechanism helps explain why iodine-based antiseptics can retain activity against organisms resistant to certain antibacterial medicines.
The research reported strong activity against both resistant and susceptible bacterial strains, alongside rapid killing of the two tested Candida species. Such findings support continued investigation of molecular iodine in settings where reducing microbial burden is important. However, the study did not test whether these formulations remove established nasal colonization, prevent wound infections or interrupt transmission between patients and healthcare workers.
The distinction between disinfecting a laboratory suspension and preventing infection is especially important. Microorganisms encountered in practice may be embedded within organic material, associated with biofilms or protected by the physical characteristics of skin and medical equipment. These conditions can affect how much active antiseptic reaches the organism and how long adequate contact is maintained.
How does I2Pure molecular iodine differ from conventional povidone-iodine antiseptics?
Povidone-iodine is a widely used antiseptic in which iodine is associated with a polymer that acts as a reservoir for the antimicrobial species. Molecular iodine is responsible for an important part of the formulation’s antimicrobial activity, but its availability depends on the chemical equilibrium among different iodine species. I2Pure’s development approach focuses on delivering active molecular iodine through alternative stabilization and carrier systems.
The formulations examined in the study differed substantially in composition. The aqueous soak contained a starting titratable iodine concentration of approximately 1,500 parts per million, while the propylene glycol-based nasal preparation contained approximately 2,500 parts per million. The skin antiseptic contained approximately 300 parts per million of iodine and was formulated with 70% isopropyl alcohol and a viscosity-modifying polymer.
These differences matter when attributing antimicrobial activity to the iodine component. Isopropyl alcohol has established antimicrobial activity of its own, meaning results for the alcohol-containing preparation cannot automatically be attributed exclusively to molecular iodine. A more detailed comparison involving matched formulations without the iodine component would help quantify the additional contribution of iodine within each delivery system.
The published study compared molecular iodine formulations directly with povidone-iodine for textile staining, but it did not establish comprehensive head-to-head superiority in antimicrobial efficacy using matched conditions across the pathogen panel. Historical findings concerning povidone-iodine provide useful context, but differences in testing methods, concentrations and formulations limit direct performance comparisons. The research supports rapid antimicrobial activity and reduced staining, rather than a definitive conclusion that I2Pure is clinically superior to existing antiseptics.
Did the I2Pure formulations eliminate staining on hospital gowns, linens and scrubs?
The textile experiments provide one of the clearest practical findings in the study. Researchers applied the three molecular iodine formulations and conventional povidone-iodine to five types of hospital fabric: gowns, towels, sheets, scrubs and baby linens. The treated materials were allowed to dry for four days before being rinsed under running water for 30 seconds.
The molecular iodine formulations were almost completely removed from the tested materials after rinsing, while visible povidone-iodine staining persisted. Researchers observed slight residual staining from the soak formulation on towels, scrubs and baby linens, indicating that the results support substantially reduced persistent staining rather than an absolute absence of staining under every condition. The materials were primarily cotton and polyester blends, and the experiments were conducted on small fabric samples.
This distinction has practical relevance for healthcare facilities, where repeated antiseptic exposure can contribute to staining of clothing, linens and other materials. Products that leave less persistent discolouration could potentially reduce laundering requirements, replacement costs and operational inconvenience. However, the study did not measure actual hospital laundry expenses, fabric replacement rates or the environmental effects of repeated washing.
Further testing across different fabrics, repeated application cycles and commercial laundering processes would help determine whether the laboratory advantage produces measurable operational savings. Compatibility with surgical instruments, plastics, medical equipment and other healthcare materials would also require separate evaluation. The current evidence establishes a promising textile performance characteristic, not a completed hospital cost-effectiveness assessment.
Does the reported 24-hour antimicrobial persistence establish lasting protection?
Researchers also examined whether the formulations retained antimicrobial activity after being allowed to dry for 24 hours. The experiment involved applying each preparation to small filter-paper samples, leaving them to dry and subsequently challenging them with MRSA, Pseudomonas aeruginosa or Candida albicans. The treated samples demonstrated substantial microbial killing during a one-minute laboratory challenge after the drying period.
This result provides evidence that antimicrobial activity can persist within the dried formulation under the conditions tested. It does not demonstrate continuous killing of microorganisms throughout a full day of hospital use or establish that treated surfaces remain protected after repeated handling and cleaning. The 24-hour figure describes the interval before the microbial challenge, not a 24-hour exposure during which infection prevention was measured.
The experiments did not reproduce the full range of conditions encountered on high-touch hospital surfaces. These include repeated abrasion, contamination by bodily fluids, routine cleaning, changing humidity and repeated introduction of microorganisms. Testing on filter paper also differs from evaluating performance on stainless steel, plastic or other nonporous surfaces frequently found in clinical environments.
The United States Environmental Protection Agency has separate performance expectations for disinfectants making residual antimicrobial claims, including relevant efficacy and durability testing. The laboratory persistence findings therefore do not establish an EPA-authorised 24-hour residual disinfectant claim. Additional standardized studies would be necessary to support such a claim for a specific commercial formulation and intended surface application.
What safety and regulatory evidence would be required for wider clinical use?
The three formulations address potentially different applications, making their regulatory requirements particularly important. A topical skin antiseptic, a preparation intended for nasal decolonization and a hospital surface disinfectant may fall under different regulatory frameworks depending on their composition, intended use and product claims. Evidence supporting one application cannot automatically be extended to another.
In the United States, topical antiseptic drug products are generally subject to Food and Drug Administration requirements, including applicable over-the-counter drug monograph provisions or product-specific approval pathways. Environmental disinfectants making public-health antimicrobial claims generally require Environmental Protection Agency registration and supporting efficacy data. A product described as a nasal antiseptic must also be assessed against the regulatory requirements applicable to its particular intended use.
I2Pure already markets selected consumer-oriented molecular iodine products and is pursuing additional healthcare applications. However, the October study does not announce a new FDA approval, an EPA registration or clearance for the experimental formulations to prevent specified hospital infections. The availability of certain consumer products should not be interpreted as authorisation for all potential surgical, wound-care or environmental uses.
Clinical safety also remains an important consideration. The published investigation focused primarily on antimicrobial killing, staining and residual activity rather than prospective human tolerability or infection prevention outcomes. Skin irritation, local tissue compatibility, systemic exposure and formulation-specific effects may require investigation according to the intended application.
The nasal formulation, for example, would require evidence appropriate to exposure of nasal tissues, while a surgical or wound-care preparation would need assessment within its intended clinical setting. The absence of toxicity findings in earlier laboratory models cannot establish that every concentration and formulation will be suitable for repeated use in patients. Product-specific safety evidence and appropriate manufacturing controls will remain central to commercialization.
How independent is the published research, and what limitations affect its interpretation?
The study was led by Elisabet Bjånes and researchers affiliated with the University of California San Diego, and its publication in the peer-reviewed journal Antimicrobial Agents and Chemotherapy provides scientific scrutiny beyond the company’s own announcement. However, the research was conducted under a sponsored research agreement with I2Pure. The author disclosures also identify Ilker Bayer as an I2Pure employee and Victor Nizet as a company consultant.
Those relationships do not invalidate the experimental results, but they are relevant when assessing the degree of commercial involvement and the need for reproducibility. Further testing by independent laboratories, particularly using standardized antimicrobial methods and appropriate formulation controls, would strengthen confidence in the findings. Replication across multiple pathogen isolates would also help determine whether the observed performance applies consistently beyond the selected laboratory strains.
The experimental programme was relatively narrow in some important respects. Only 17 microbial strains were evaluated, and the killing assays were conducted primarily in controlled suspensions rather than on infected tissue or under actual clinical conditions. The persistence experiments involved three representative organisms on filter paper, while the staining evaluation involved selected hospital textiles under a single defined rinsing procedure.
The research also did not demonstrate prevention of healthcare-associated infections, reductions in antibiotic use or improved patient recovery. Those outcomes would require appropriately designed clinical or real-world investigations. The strongest evidence currently concerns microbial killing under defined exposure conditions and material performance in the tested laboratory systems.
Could the molecular iodine platform create commercial opportunities in hospital antiseptics and infection control?
I2Pure is developing its technology as a platform that can be incorporated into different antimicrobial products and delivery systems. The company identifies potential applications involving healthcare antiseptics, wound care, medical devices, industrial biosafety and other settings where microbial control is important. Its commercial strategy includes licensing arrangements, product development and the ability to manufacture formulations for different partners and applications.
The company has disclosed a perpetual global licensing agreement with a multinational healthcare business and has expanded its manufacturing activities in Asheville, North Carolina. Those developments suggest that I2Pure is moving beyond laboratory research toward broader commercialization. However, the company has not disclosed financial details sufficient to establish the revenue contribution from the licensing arrangement or the scale of future demand.
The newly published evidence could support commercial discussions with healthcare manufacturers and institutional customers seeking alternatives to conventional iodine-based antiseptics. Rapid antimicrobial activity, reduced fabric staining and residual activity after drying are potentially useful product characteristics. Their financial value will depend on whether manufacturers can reproduce the performance consistently, obtain applicable regulatory authorisations and offer products at competitive prices.
Healthcare purchasing decisions also involve established infection-control protocols, staff training, product compatibility, supply reliability and cost per application. Hospitals are unlikely to replace existing antiseptics solely on the basis of favourable laboratory results if comparative clinical evidence, product-specific claims or practical implementation data remain incomplete. Demonstrating performance under routine use conditions will therefore be more commercially informative than simply expanding the list of organisms killed in laboratory assays.
What must I2Pure demonstrate before the laboratory findings support hospital adoption?
The next meaningful development would be a programme of standardized, application-specific testing that connects the reported antimicrobial activity with the actual conditions in which the products are intended to be used. For a topical or nasal antiseptic, the relevant evidence could include local tolerability, microbial burden reduction and appropriately designed clinical assessments. For environmental disinfection, validation would need to reflect the surfaces, contamination levels and durability requirements associated with intended product claims.
Comparative testing will be particularly important because povidone-iodine, alcohol-based antiseptics and other established antimicrobial products already have extensive clinical experience. A new formulation may offer practical advantages without necessarily providing superior infection prevention. Establishing a meaningful distinction requires evidence that addresses the intended use rather than relying exclusively on laboratory killing percentages.
Manufacturing consistency and stability will also influence commercial viability. Molecular iodine formulations must maintain appropriate active concentrations throughout their intended shelf life, while packaging, temperature exposure and formulation composition can affect product performance. Larger-scale production will need to reproduce the characteristics observed in laboratory preparations.
The published findings provide a meaningful scientific foundation for I2Pure’s molecular iodine technology, particularly its rapid activity against several multidrug-resistant pathogens and reduced staining of tested hospital fabrics. They also reveal limits that are important for clinical interpretation, including variable activity against certain fungi, formulation-specific effects and the absence of direct patient infection outcomes.
For I2Pure, the central commercial opportunity is to establish whether these formulation advantages can be delivered reliably, safely and economically in products suitable for regulated healthcare applications. The October 2026 study demonstrates promising laboratory antimicrobial performance, but the more consequential evidence will come from independent replication, intended-use testing and clinical or environmental validation showing that the benefits persist beyond controlled experimental conditions.
